Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Your prescriber will screen for personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN 2) before initiating treatment
With the development of pharmacological therapies, alongside lifestyle and surgical interventions, clinicians must now evaluate: Whether a treatment is effective How early a response can be detected Which patients may require adjustments in their management plan This shift highlights a clear gap in current clinical practice: the lack of accessible, non-invasive tools that reflect ongoing liver injury and response to therapy
The final cost depends on the case and is confirmed at consultation
The renal impairment study excluded participants who required dialysis and while renal clearance is a focus of this study, this can be seen as a limitation
